Search | IOVS | ARVO Journals

Showing 1 – 20 of 25

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract September 2016

Lymphatic Vessel Area is increased in Lid Margins of Graft-versus-Host Disease Mice

Regine Vogt; Christin Riegel; Petra Hoffmann; Matthias Edinger; Diana Pauly; Horst Helbig; Tina Dietrich-Ntoukas

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2417. doi:

ARVO Annual Meeting Abstract September 2016

Navigated retinal photocoagulation (NaviLas®) as an alternative therapy in patients with refractory central serous chorioretinopathy

Jan Klonner; Juliane Schlomberg; Anne Rübsam; Tina Dietrich-Ntoukas; Sibylle Winterhalter; Antonia Joussen; Bert Müller

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5359. doi:

ARVO Annual Meeting Abstract June 2013

Characterization of patients with ocular chronic graft-versus-host disease and evaluation of a new grading scale

Christiane Blecha; Daniel Wolff; David Maerker; Horst Helbig; Tina Dietrich-Ntoukas

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):5420. doi:

ARVO Annual Meeting Abstract April 2010

Modulation of Cytokine Expression by Protein Tyrosine Phosphatase 1b Treatment in Retinal Pigment Epithelial Cells

D. A. Maerker; R. Foeckler; V. Milenkovic; O. Strauss; H. Helbig; T. Dietrich

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):467. doi:

Cornea May 2009

Safety Profile of Topical VEGF Neutralization at the Cornea

PDF

Felix Bock; Jasmine Onderka; Carmen Rummelt; Tina Dietrich; Björn Bachmann; Friedrich E. Kruse; Ursula Schlötzer-Schrehardt; Claus Cursiefen
TAGS: antibodies, bevacizumab, cornea, eyedrops, neutralization, safety, vascular endothelial growth factor a, anti-vascular endothelial growth factor therapy, epithelium, wound healing
Invest. Ophthalmol. Vis. Sci.. 2009; 50(5):2095-2102. doi: https://doi.org/10.1167/iovs.07-1129

ARVO Annual Meeting Abstract April 2009

Profile of Cytokines in the Tear Fluid of Patients With Dry-Eye Disease

C. Jacobi; P. Lewczuk; T. Dietrich; C. Cursiefen; F. Kruse

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):2613. doi:

ARVO Annual Meeting Abstract May 2008

Safety Profile of Topical VEGF-Neutralization at the Cornea Using Bevacizumab Eye Drops in a Murine Model

C. Cursiefen; F. Bock; T. Dietrich; B. Bachmann; C. Rummelt; U. Schlötzer-Schrehardt; F. E. Kruse

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):1469. doi:

ARVO Annual Meeting Abstract May 2008

Lymphatic Vessels Determine the High-Risk Status of Vascularized Recipient Corneas

F. Bock; D. Hos; T. Dietrich; J. Onderka; B. Bachmann; F. E. Kruse; S. J. Wiegand; C. Cursiefen

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):1484. doi:

ARVO Annual Meeting Abstract May 2008

Integrin Alpha 5 Inhibition Improves Corneal Graft Survival in a Murine Model of High-Risk Keratoplasty

T. Dietrich; J. Onderka; F. Bock; D. Hos; G. Zahn; R. Stragies; F. E. Kruse; C. Cursiefen

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):5761. doi:

Cornea May 2008

Inflammatory Corneal (Lymph)angiogenesis Is Blocked by VEGFR-Tyrosine Kinase Inhibitor ZK 261991, Resulting in Improved Graft Survival after Corneal Transplantation

PDF

Deniz Hos; Felix Bock; Tina Dietrich; Jasmine Onderka; Friedrich E. Kruse; Karl-Heinz Thierauch; Claus Cursiefen
TAGS: cornea, graft survival, keratoplasty, protein-tyrosine kinase inhibitor, vascular endothelial growth factor receptors, kinase inhibitors, tyrosine, angiogenesis, lymph, lymphangiogenesis
Invest. Ophthalmol. Vis. Sci.. 2008; 49(5):1836-1842. doi: https://doi.org/10.1167/iovs.07-1314

Cornea June 2007

Bevacizumab as a Potent Inhibitor of Inflammatory Corneal Angiogenesis and Lymphangiogenesis

PDF

Felix Bock; Jasmine Onderka; Tina Dietrich; Björn Bachmann; Friedrich E. Kruse; Matthias Paschke; Grit Zahn; Claus Cursiefen
TAGS: bevacizumab, corneal neovascularization, lymphangiogenesis, vascular endothelial growth factor a
Invest. Ophthalmol. Vis. Sci.. 2007; 48(6):2545-2552. doi: https://doi.org/10.1167/iovs.06-0570

ARVO Annual Meeting Abstract May 2007

Aqueous Humour Displays Antilymphangiogenic Effects

F. Bock; J. Onderka; T. Dietrich; B. Bachmann; F. Kruse; C. Cursiefen

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):3200. doi:

ARVO Annual Meeting Abstract May 2007

Tumor-Associated Lymphangiogenesis as Novel Prognostic Marker for Metastasis of Conjunctival Malignant Melanomas

P. Zimmermann; T. Dietrich; F. Bock; C. Rummelt; F. E. Kruse; C. Cursiefen

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):4799. doi:

ARVO Annual Meeting Abstract May 2007

Effect of Integrin Alpha 5 Inhibition on Lymphangiogenesis and Recruitment of CD11b-Positive Macrophages in a Murine Model of High-Risk Keratoplasty

T. Dietrich; J. Onderka; F. Bock; D. Hos; G. Zahn; R. Stragies; F. E. Kruse; C. Cursiefen

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):181. doi:

ARVO Annual Meeting Abstract May 2007

Tyrosine Kinase Inhibitors Block Inflammatory Corneal Hem- and Lymphangiogenesis and Improve Graft Survival After Corneal Transplantation

D. Hos; F. Bock; T. Dietrich; J. Onderka; F. E. Kruse; K. H. Thierauch; C. Cursiefen

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):1696. doi:

ARVO Annual Meeting Abstract May 2006

Role of Glial Cell Derived Neurotrophic Factors in Corneal Epithelial Wound Healing

F.E. Kruse; T. Dietrich; M. Zenkel; A. Ohlmann; J. Joergensen; U. Schloetzer–Schrehardt

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):2723. doi:

ARVO Annual Meeting Abstract May 2006

Inhibition Of Inflammatory Lymphangiogenesis In The Cornea By Blocking Integrin Alpha 5

T. Dietrich; J. Onderka; F. Bock; G. Zahn; R. Stragies; F.E. Kruse; C. Cursiefen

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):3907. doi:

ARVO Annual Meeting Abstract May 2006

Bevacizumab (Avastin) as a Potent Inhibitor of Inflammatory Hem– and Lymphangiogenesis in the Cornea

F. Bock; J. Onderka; T. Dietrich; B. Bachmann; F. Kruse; C. Cursiefen

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):3908. doi:

ARVO Annual Meeting Abstract May 2006

Inflammatory Corneal Lymphangiogenesis is Inhibited by Blocking Vegfr3–Signalling

J. Onderka; F. Bock; T. Dietrich; B. Pytowski; F. Kruse; C. Cursiefen

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):3909. doi:

ARVO Annual Meeting Abstract May 2006

Phenotypic Characterization of Human Limbal Epithelial Cells Expanded on Fibrin Gels

U.S. Schrehardt; C. Cursiefen; T. Dietrich; C. Hofmann–Rummelt; F.E. Kruse

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):3945. doi:

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Lymphatic Vessel Area is increased in Lid Margins of Graft-versus-Host Disease Mice

Navigated retinal photocoagulation (NaviLas®) as an alternative therapy in patients with refractory central serous chorioretinopathy

Characterization of patients with ocular chronic graft-versus-host disease and evaluation of a new grading scale

Modulation of Cytokine Expression by Protein Tyrosine Phosphatase 1b Treatment in Retinal Pigment Epithelial Cells

Safety Profile of Topical VEGF Neutralization at the Cornea

Profile of Cytokines in the Tear Fluid of Patients With Dry-Eye Disease

Safety Profile of Topical VEGF-Neutralization at the Cornea Using Bevacizumab Eye Drops in a Murine Model

Lymphatic Vessels Determine the High-Risk Status of Vascularized Recipient Corneas

Integrin Alpha 5 Inhibition Improves Corneal Graft Survival in a Murine Model of High-Risk Keratoplasty

Inflammatory Corneal (Lymph)angiogenesis Is Blocked by VEGFR-Tyrosine Kinase Inhibitor ZK 261991, Resulting in Improved Graft Survival after Corneal Transplantation

Bevacizumab as a Potent Inhibitor of Inflammatory Corneal Angiogenesis and Lymphangiogenesis

Aqueous Humour Displays Antilymphangiogenic Effects

Tumor-Associated Lymphangiogenesis as Novel Prognostic Marker for Metastasis of Conjunctival Malignant Melanomas

Effect of Integrin Alpha 5 Inhibition on Lymphangiogenesis and Recruitment of CD11b-Positive Macrophages in a Murine Model of High-Risk Keratoplasty

Tyrosine Kinase Inhibitors Block Inflammatory Corneal Hem- and Lymphangiogenesis and Improve Graft Survival After Corneal Transplantation

Role of Glial Cell Derived Neurotrophic Factors in Corneal Epithelial Wound Healing

Inhibition Of Inflammatory Lymphangiogenesis In The Cornea By Blocking Integrin Alpha 5

Bevacizumab (Avastin) as a Potent Inhibitor of Inflammatory Hem– and Lymphangiogenesis in the Cornea

Inflammatory Corneal Lymphangiogenesis is Inhibited by Blocking Vegfr3–Signalling

Phenotypic Characterization of Human Limbal Epithelial Cells Expanded on Fibrin Gels

To View More...

You must be signed into an individual account to use this feature.